ZVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
ZEVRA THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$10.16+0.22 (+2.21%)
Close on Oct 19, 2026
- Market cap
- $623.18M
- P/E (TTM)
- 10.9
- Dividend yield
- –
ZEVRA THERAPEUTICS, INC. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| MIPLYFFA | $87.40M | $10.10M | – | – | – | – | – | 82.1% | +765.3% |
| OLPRUVA | $800.00K | $100.00K | $0 | – | – | – | – | 0.8% | +700.0% |
| Reimbursement of Out-of-pocket Third-party Research and Development Costs [Member] | – | – | – | – | – | – | $1.10M | – | – |
| Consulting Services [Member] | – | – | – | $100.00K | $100.00K | $1.70M | $0 | – | – |
| License | – | – | – | – | – | – | $12.80M | – | – |
By region
From the segment and revenue-disaggregation notes of Zevra Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.